Despite these updates, the overall demand for Covid-19 vaccines has significantly decreased over the past year. Both Pfizer and Moderna have experienced sharp declines in sales, with Pfizer’s 2023 revenue dropping by 42% compared to the previous year, prompting cost-saving measures. Moderna reported a 64.8% decrease in revenue for 2023, highlighting the broader market challenges faced by vaccine manufacturers.
Pfizer and BioNTech are also exploring new avenues, including the development of a combination mRNA vaccine targeting both influenza and Covid-19. However, this combination therapy recently did not meet one of its two primary endpoints in a Phase III trial.
In May, Novavax entered into a $1.2 billion licensing agreement with Sanofi, granting the latter global commercialization rights for its adjuvanted Covid-19 vaccine, except in markets where Novavax already has existing partnerships, such as India, South Korea, and Japan.
Novavax’s EUA for its updated Covid-19 vaccine arrives amid a backdrop of strategic shifts and continued efforts to address the evolving landscape of Covid-19 variants. The updated vaccine, distinguished as the only protein-based Covid-19 vaccine available in the U.S., utilizes noninfectious copies of the Covid spike protein to prime the immune system. While Moderna and Pfizer’s boosters target the KP.2 variant, Novavax’s shot is aimed at the parent JN.1 strain, which has demonstrated robust cross-reactivity against multiple circulating variants.
This authorization enables Novavax to make its updated vaccine available in pre-filled syringes at numerous locations across the United States, expanding the options for Covid-19 vaccination in the country.
https://finance.yahoo.com/news/novavax-wins-fda-emergency-approval-145333025.html
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Vironexis Biotherapeutics Launches with FDA Clearance for First AAV-Delivered Cancer Immunotherapy Trial
SAN DIEGO, Calif., September 12, 2024 – Vironexis Biotherapeutics has launched from stealth, announcing FDA clearance of its IND application for VNX-101, a gene therapy targeting CD19+ acute lymphoblastic leukemia. This marks the first-ever clinical trial of an...
AAV Gene Therapy Revolutionizes Treatment for LCA1, Improving Vision Significantly
Innovative AAV Gene Therapy Dramatically Restores Vision in LCA1 Researchers have made a significant breakthrough in treating Leber congenital amaurosis type 1 (LCA1), a severe inherited retinal disease that causes early childhood blindness, by using an innovative...
Cellular Origins & 3P Innovation Partner to Streamline Cell and Gene Therapy Manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has partnered with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P...
Voyager Therapeutics Expands Gene Therapy Portfolio with Novartis License for Next-Generation Capsid
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has entered into a licensing agreement with Novartis AG (NYSE: NVS) for a novel capsid developed using Voyager’s TRACER™ capsid discovery platform. This license will...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE